Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Lewy Body Dementia - Pipeline Review, H2 2016 - Research and Markets

Research and Markets
Posted on: 28 Oct 16

Research and Markets has announced the addition of the "Lewy body Dementia - Pipeline Review, H2 2016" report to their offering.

Lewy body Dementia Lewy Body Dementia (also called Dementia with Lewy bodies) is a form of dementia that shares characteristics with both Alzheimer's and Parkinson's diseases. Lewy bodies are abnormal microscopic protein deposits in the brain that disrupt the brain's normal functioning causing it to slowly deteriorate. Symptoms include visual hallucinations, movement disorders, cognitive problems and depression. Risk factors include age and family history. Treatment includes cholinesterase inhibitors, antipsychotic and Parkinson's disease medications.

Lewy body Dementia pipeline therapeutics constitutes close to 11 molecules. Out of which approximately 11 molecules are developed by Companies. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 5, 2 and 1 respectively.

Lewy body Dementia - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Lewy body Dementia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Lewy body Dementia and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. Lewy Body Dementia Overview
  3. Therapeutics Development
  4. Pipeline Products for Lewy Body Dementia - Overview
  5. Pipeline Products for Lewy Body Dementia - Comparative Analysis
  6. Lewy Body Dementia - Therapeutics under Development by Companies
  7. Lewy Body Dementia - Therapeutics under Investigation by Universities/Institutes
  8. Lewy Body Dementia Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Lewy Body Dementia - Products under Development by Companies
  13. Lewy Body Dementia - Products under Investigation by Universities/Institutes
  14. Lewy Body Dementia - Companies Involved in Therapeutics Development
  • Axovant Sciences Ltd.
  • BioArctic AB
  • Eisai Co., Ltd.
  • Immungenetics AG
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Takeda Pharmaceutical Company Limited

For more information about this report visit

View source version on

Business Wire

Last updated on: 28/10/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.